In Europe’s medical cannabis market, the cultivar name on the label does not always guarantee what is inside. As Business of Cannabis reported on 27 October, the MHRA, the UK medicines regulator, has raised concerns with clinicians and clinics about the recreational-style brand names that are common in the medical market. Behind that debate sits a less comfortable issue for the industry: the genetic instability of many commercial cultivars.
A brand name is not a variety
A conventional medicine is identified by its active ingredient and its dose. Cannabis flower, by contrast, is still sold under names inherited from the consumer market, and those names do not guarantee a consistent chemical profile. Davis Allen, a researcher at the University of British Columbia, argues in the report that strain names have lost most of their meaning. His example: at least five companies sell a “Pink Kush”, and in his view none of them carries the original’s signature scent.
Steven Tan, CEO of Jersey-based Northern Leaf, estimates that most cultivars trace back to between 50 and 100 parent lines. Ten seeds from the same batch can produce plants with noticeably different THC and terpene levels. For a patient on a repeat prescription, the same label can hide a different product.
Intellectual property is starting to move
The way out the sector is proposing is registered, stable varieties. Plant variety protection, granted in the EU by the Community Plant Variety Office (CPVO), requires a variety to be distinct, uniform and stable. That is the opposite of genetics that shift from batch to batch.
Some companies have already moved. Aurora Cannabis secured EU community plant variety rights from the CPVO for two proprietary varieties early in 2026, and in May it announced Canadian plant breeders’ rights for Farm Gas and Driftwood Diesel, both sold as medical cannabis in Germany, Poland, the UK, Canada and Australia. According to Business of Cannabis, Aurora has said it will defend its genetics in court. Organigram, meanwhile, has committed up to US$10m to Phylos Bioscience for THCV and rare-cannabinoid seed lines.
Why it matters in Europe and Spain
Europe’s medical markets are being built around standardised products. In Spain, Royal Decree 903/2025 relies on standardised preparations registered with the AEMPS, and hospital pharmacy dispensing has just begun with only two preparations available. In that context, genetic traceability stops being a growers’ concern and becomes a commercial requirement: anyone who cannot show their flower is the same batch after batch will struggle with hospitals, distributors and regulators.
Allen expects registered cultivars to become the norm within five to ten years, and is pushing for a centralised gene bank and mandatory DNA fingerprinting. Tan estimates that genetics account for around 30% of the value a cultivation cycle creates, and expects the market to narrow to about ten outperforming cultivars.
Business implications
- Producers: registering and protecting proprietary varieties becomes a tradeable asset and a barrier to entry.
- Laboratories: demand grows for DNA fingerprinting and testing that verifies batch-to-batch consistency, not just potency.
- Distributors and importers: supply contracts should require documentation of genetic origin.
- Brands: recreational-style names may become a regulatory risk in medical channels.
Genetics, standardisation and intellectual property are issues best settled by sitting down with the right people. At Spannabis B2B Bilbao 2027, on 11 March in the VIP Room of the BEC, producers, laboratories, distributors and investors will have that space. Get your ticket or book a B2B table to meet the companies already making their move.